Alogliptin Impurity 24(CAS: 4318-56-3)

Alogliptin Impurity 24 (CAS: 4318-56-3) is a specific byproduct or contaminant associated with the synthesis of alogliptin, a DPP-4 inhibitor used in diabetes treatment. It is a pharmaceutical impurity with a molecular structure related to the parent compound, often requiring analysis to ensure drug purity and safety. Its exact chemical formula and physical properties depend on the synthesis pathway, but it is typically characterized by its presence in trace amounts during quality control testing.

Alogliptin Impurity 24 (CAS: 4318-56-3) is primarily used in pharmaceutical research for the identification and analysis of impurities in drug manufacturing processes. It plays a critical role in ensuring the purity of alogliptin, a medication for type 2 diabetes, and is also relevant in drug development for compliance with regulatory standards. Its presence is monitored to assess potential safety risks and optimize synthetic methods.

Alogliptin Impurity 24 (CAS: 4318-56-3) is not intended for therapeutic use and is generally considered safe in controlled environments when handled properly. However, as a chemical impurity, it may pose risks if exposed in high concentrations. Safety precautions include wearing protective gear and following standard laboratory protocols. Its toxicity profile is typically low, but specific safety data should be referenced based on its chemical structure and impurity classification.

Alogliptin Impurity 24 (CAS: 4318-56-3) should be stored in a cool, dry place, away from direct light, in airtight containers to maintain stability. It is typically kept at 2-8°C to prevent degradation, and humidity levels should be controlled to avoid moisture-related reactions. Proper storage ensures its integrity for analytical testing and adherence to pharmaceutical quality standards.